Essentials of Clinical Research - part 2 doc

... FraminghamPopulation 24 2,800 62, 910% African-American 73.5 5.1Age 25 –44 30 3545–64 20 22 6 5-& gt; 14 13Median Income $ 26 ,700 55,300Education<High School 25 13High School 28 23 >High School ... systematic review. Jama. Nov 2 2005 ;29 4(17) :22 0 3 -2 20 9.14. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ. 1948;ii:76 9-7 82. 15. Reviews of statistical and economic ... 10% 20 % 30% 50%Rate in the “control” treatment 2% 1.8% 1.6% 1.4% 1% 97,959 23 ,22 3 9,757 3,104 3% 2. 7% 2. 4% 2. 1% 1.5% 64,673 15,339 6,447 2, 053 5% 4.5% 4.0% 3.5% 2. 5% 38,044 9,0 32 3,800 1 ,21 2...

Essentials of Clinical Research - part 1 doc

... time. Essentials of Clinical Research Part IThis Part addresses traditional clinical research, beginning with the history of the development of clinical research, to traditional clinical research ... controlled clinical trials. BMJ. May 25 , 1991; 3 02( 6787): 127 1– 127 2. 7. Amberson JB, MacMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonary tubercu-losis. Am Rev Tuber. 1931; 24 :401–435. ... specifically geared to the clinical researcher interested in conductingS.P. Glasser (ed.), Essentials of Clinical Research, 3© Springer Science + Business Media B.V. 20 08List of AbbreviationsA Diabetes...

Essentials of Clinical Research - part 5 docx

... of patients No. dead No. aliveTotal no. of patients No. dead No. alive1 615 49 566 624 67 557 2 758 44 714 771 64 7073 317 27 29 0 309 32 2774 8 32 1 02 730 850 126 724 5 810 85 725 406 52 ... Treatment-placeboStudy Mortality rate Mortality rate Diff SE of diff P-value1 0.0797 0.1074 −0. 027 7 0.0165 0.047 2 0.0580 0.0830 −0. 025 0 0.0131 0. 028 3 0.08 52 0.1036 −0.0184 0. 023 4 0 .21 64 0. 122 6 ... 810 85 725 406 52 3546 2, 267 24 6 2, 021 2, 257 21 9 2, 038Total 5,599 553 5,046 5 ,21 7 560 4,657Table 10.3 The individual mortality rates the six studies included in the meta-analysisMortality ratesIndividual...

Essentials of Clinical Research - part 9 doc

... trial 27 5/1,115 22 8/1,116 0. 828 1/(0 .24 7 −( 42 months) (24 .7%) (20 .4%) 0 .20 4) 23 .5 (24 )ISIS 4 (5 weeks) 2, 231 /29 , 022 2, 088 /29 , 028 0.936 1/(0.0769 (7.69%) (7.19%) − 0.0719) 20 1.1 (20 2)18 ... clinical trials? Beware the sound of sirens. Stroke 20 05; 36:1 622 –1 623 . 2. Berry D. Is the Bayesian approach ready for prime time? Yes! Stroke 20 05; 26 : 1 621 –1 622 .18 It’s All About Uncertainty ... Yes 20 11 31Attend course No 8 12 20 Total 28 23 16 Association, Cause, and Correlation 28 9line, multivariate or multivariable regression, etc.). We use the term regression to imply a co-relationship,...

Essentials of Clinical Research - part 3 ppt

... Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. Nov 23 , 20 00; 343 (21 ):1 520 –1 528 , 1 522 p following 1 528 .34. ... 28 1(13): 122 0– 122 2.5 Postmarketing Research 75phase III trials, nor do they provide information on long-term effectiveness and safety. All of the restrictions characteristic of controlled clinical ... phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheuma-toid arthritis. Can J Clin Pharmacol. Fall 20 05; 12( 3):e254 26 3.10. Gex-Fabry...

Essentials of Clinical Research - part 4 potx

... May 25 , 1994; 27 1 (20 ):1609–1614. 2. Benson H, Epstein MD. The placebo effect. A neglected asset in the care of patients. JAMA.June 23 , 1975; 23 2( 12) : 122 5– 122 7. 3. Melmon K, Morrelli H, Hoffman ... Services FaDA, ed. Vol 21 U.S.C. 3 52 (n).41. Section 5 02( n) of the Food Drug and Cosmetics Act, and Title 21 Code of Federal Regulations. Vol 20 2.1(j)(1). 42. Section 5 02 (n) of the Food Drug and ... Act, and Title 21 Code of Federal Regulations. Vol 20 2.1.43. 21 CFR Part 310 section 5 02( a) of the Food and Drug Administration Modernization Act of 1997 (Modernization Act). Vol 21 314.81(b)(3).44....

Essentials of Clinical Research - part 6 ppsx

... issue 2. Chichester: Wiley; 20 07. 21 . Panda A, Dorairajan L, Kumar S. Application of evidence-based urology in improving quality of care. Indian J Urol 20 07; 23 (2) :91–96. 22 . The Problem of Induction ... inconsistency in meta-analyses. BMJ. Sept 6, 20 03; 327 (7414):557–560.16. Chalmers I, Hedges LV, Cooper H. A brief history of research synthesis. Eval Health Prof.Mar 20 02; 25 (1): 12 37.17. Wells ... drug AJ Allergy Clin Immunol 20 02; 109(4):63 6-6 43; JAMA 1997 ;27 7 (11):88 7-8 91; Pediatrics, 20 01;107 (4):70 6-7 11.Fig. 12. 4 Immortal time bias in exposed (study) and non-exposed (control) groups194...

Essentials of Clinical Research - part 7 ppt

... conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis”. JAMA. Dec 1, 20 04; 29 2 (21 ) :26 55 26 57; discussion 26 58 26 59. 21 6 M. ... Should we use a case-crossover design? Annu Rev Public Health. 20 00; 21 :193 22 1.54. Marshall RJ, Jackson RT. Analysis of case-crossover designs. Stat Med. Dec 30, 1993; 12( 24) :23 33 23 41.55. Donnan ... case-crossover and case-time-control designs in pharmacoepidemi-ology. Pharmacoepidemiol Drug Saf. May 20 01; 10(3) :25 9 26 2.56. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic...

Essentials of Clinical Research - part 8 ppsx

... number of events not occurring (i.e. non events, or p/p-1,). So if blood type O occurs in 42% of people, the odds of someone having a blood type of O are 0. 42/ 1-0 . 42 i.e. the odds of a randomly ... differences in 14 Research Methodology for Studies of Diagnostic Tests 25 3Fig. 14.6 Comparison of ROC curvesFig. 14.7Box 1 2- 1 . Receiver operating characteristic curve for cutoff levels of B-type natriuretic ... Nov–Dec 20 06; 21 (6 Suppl 1):S2–16; quiz S17–19.8. Fagan TJ. Nomogram for Bayes’s theorem (C). N Engl J Med. 1975; 29 3 :25 7. 27 0 J.M. OakesThe term Za / 2 is the value of a Z statistic (often...

Essentials of Clinical Research - part 10 pptx

... 170–174, 1 92, 193, 195, 199, 20 2, 20 6, 20 7, 20 9 21 7, 22 3, 22 5 22 7, 22 9, 23 0, 23 2, 23 4 24 0, 24 2, 25 0, 26 9 27 1, 27 3, 27 4, 27 6, 27 8, 28 3, 28 8 29 1, 29 4 29 7, 29 9, 300, 3 02 305, 309, 310, 3 12, 314, ... 34–36, 44, 173, 197, 20 2, 21 4, 21 6, 23 2, 27 9, 29 6, 29 9, 303–305, 314, 316, 317confounding 10, 30, 35, 72, 78, 134, 20 0, 20 2, 20 9, 21 1, 21 2, 21 6, 23 2, 23 5, 27 6, 29 5, 29 7, 29 8, 29 9–305, 317, 333congestive ... 118– 121 , 128 , 130–1 32, 165, 166, 171, 174, 187, 189, 191, 195, 199, 20 9, 21 2, 21 6, 23 2, 23 8, 23 9, 25 1, 25 2, 26 8, 27 1, 28 5 28 7, 29 4, 29 6, 29 8–300, 303, 304, 3 12, 313, 315, 317odds ratio 1 72 174,...

Xem thêm